Prostate Cancer Clinical Trials in Denver, Colorado
7 studies are recruiting for prostate cancer in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…
- Stage
- Phase 1
- Ages
- 12 and older
- Site
- Rocky Mountain Cancer Center, Denver, Colorado
- Locations
- 77 in total
- Run by
- PMV Pharmaceuticals, Inc
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute at HealthOne, Denver, Colorado
- Locations
- 39 in total
- Run by
- Eli Lilly and Company
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute - Denver DDU, Denver, Colorado
- Locations
- 10 in total
- Run by
- Nammi Therapeutics Inc
-
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…
- Stage
- Phase 3
- Ages
- 18 to 100
- Site
- Rocky Mountain Cancer Centers, Denver, Colorado
- Locations
- 95 in total
- Run by
- Novartis Pharmaceuticals
-
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- AdventHealth Medical Group Urology of Denver, Denver, Colorado
- Locations
- 337 in total
- Run by
- Pfizer
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Mult…
- Stage
- EARLY_Phase 1
- Ages
- 18 and older
- Site
- UCHealth-Metro Denver, Denver, Colorado
- Locations
- 4 in total
- Run by
- University of Colorado, Denver
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute, Denver, Colorado
- Locations
- 6 in total
- Run by
- ModeX Therapeutics, An OPKO Health Company
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.